Acrivon Therapeutics Files 8-K on Financials and Operations

Ticker: ACRV · Form: 8-K · Filed: Apr 24, 2024 · CIK: 1781174

Acrivon Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAcrivon Therapeutics, Inc. (ACRV)
Form Type8-K
Filed DateApr 24, 2024
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.001, $110 million, $234 million
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations, disclosure

Related Tickers: ACRV

TL;DR

ACRV filed an 8-K detailing financial results and operational updates.

AI Summary

On April 24, 2024, Acrivon Therapeutics, Inc. filed an 8-K report. The filing primarily concerns results of operations and financial condition, Regulation FD disclosure, and other events. It also includes financial statements and exhibits, indicating updates on the company's financial status and operational activities.

Why It Matters

This filing provides crucial updates on Acrivon Therapeutics' financial health and operational activities, which are important for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As an 8-K filing, it typically contains material information that could impact stock price, but the specific details within this filing require further analysis to determine the precise risk level.

Key Players & Entities

  • Acrivon Therapeutics, Inc. (company) — Registrant
  • April 24, 2024 (date) — Date of earliest event reported
  • 001-41551 (other) — SEC File Number
  • 82-5125532 (other) — IRS Employer Identification No.
  • 480 Arsenal Way Suite 100 (other) — Principal Executive Offices Address
  • Watertown, Massachusetts (location) — Principal Executive Offices Location
  • 02472 (other) — Principal Executive Offices Zip Code
  • 617 207-8979 (other) — Registrant's Telephone Number

FAQ

What specific financial results are being reported in this 8-K filing?

The filing indicates 'Results of Operations and Financial Condition' as an item, suggesting financial results are being disclosed, but the specific figures are not detailed in the provided text.

What are the key 'Other Events' mentioned in the filing?

The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.

What is the significance of the 'Regulation FD Disclosure' item?

Regulation FD Disclosure indicates that the company is providing information to the public in a non-discriminatory manner, often related to material non-public information.

What types of 'Financial Statements and Exhibits' are included with this filing?

The filing lists 'Financial Statements and Exhibits' as an item, implying that detailed financial statements and supporting documents are part of the submission, though not provided in this excerpt.

When was Acrivon Therapeutics, Inc. incorporated or organized?

The filing states the company is incorporated in 'Delaware'.

Filing Stats: 1,116 words · 4 min read · ~4 pages · Grade level 12.4 · Accepted 2024-04-24 16:01:23

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share ACRV The Nasdaq Stock Mar
  • $110 million — rm investments balance of approximately $110 million as of March 31, 2024. The Company also
  • $234 million — rm investments balance of approximately $234 million as of March 31, 2024, after giving effe

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On April 24, 2024, Acrivon Therapeutics, Inc. (the "Company") disclosed a preliminary cash and cash equivalents and short-term investments balance of approximately $110 million as of March 31, 2024. The Company also disclosed a preliminary pro forma cash and cash equivalents and short-term investments balance of approximately $234 million as of March 31, 2024, after giving effect to the net proceeds of the Company's private placement previously disclosed on April 9, 2024. Because the Company's consolidated financial statements for the three months ended March 31, 2024 have not yet been finalized, the preliminary statement of the Company's cash and cash equivalents and short-term investments as of March 31, 2024 in this Item 2.02 is subject to change, and the Company's actual cash and cash equivalents and short-term investments as of March 31, 2024 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate. The information in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 24, 2024, the Company is hosting a virtual corporate R&D event from 4:15 p.m. to 5:30 p.m. ET. The agenda will feature presentations by the Company's leadership team, followed by an interactive Q&A session. In connection with this event, the Company posted to the "Investors & Media" section of the Company's website at ir.acrivon.com , a corporate presentation providing an update on the Company's business (the "Corporate Presentation"). In connection with this event, the Company also issued a press release (the "Press Release"). Copies of the Corporate Presentation and Press Release are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference into this Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. Phase 2b Initial Clinical Data On April 24, 2024, the Company announced initial clinical data from its ongoing registrational-intent Phase 2b clinical trial of ACR-368 in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative). The data presented was as of an April 1, 2024 data cut. A confirmed objective response rate ("ORR") (per RECIST 1.1) of 50% was observed in the prospective cohort of OncoSignature-positive patients who were efficacy-evaluable. All confirmed responders continued to be on treatment and median duration of response ("DoR") had not yet been reached. The data provided initial, prospective validation of the Acrivon Predictive Precision Proteomics ("AP3")-based ACR-368 OncoSignature assay's ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy in the ongoing clinical trial, with clear segregation of RECIST responders in the OncoSignature-positive (50% confirmed ORR in 10 patients) versus OncoSignature-negative (0% ORR in 16 patients) arms ( p-value =0.0038). In the OncoSignature-negative arm of the trial with ovarian or endometrial cancers, encouraging signs of clinical activity were observed in response to ACR-368 with ultra-low dose gemcitabine at the recommended Phase 2 combination dose, with 8 out of 16 patients having achieved stable disease. Consistent with past trials, the ACR-368 treatment-related adverse event profile was predominantly reversible and transient with only mechanism-based, hematological adverse events. Cash and Cash Equivalents and Short-term Investments As disclosed above under Item 2.02, on April 24, 2024, the Company disclosed a preliminary cash and cash equivalents and short-term investments balance of approximately $110 million as of March 31, 2024. The Company believes that its pro forma cash and cash equivalents and short-term investments of approximately $234 million as of March 31, 2024, after gi

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Acrivon Therapeutics, Inc., Presentation 99.2 Press Release, dated April 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acrivon Therapeutics, Inc. Date: April 24, 2024 By: /s/ Rasmus Holm-Jorgensen Rasmus Holm-Jorgensen Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.